Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
First Claim
1. A pharmaceutical composition for use in cytostatic or immunotherapy, comprising a component I and a component II, wherein said component I comprises at least one compound that produces necroses a in tumor or in an inflammatory process, said necroses resulting in the release of at least one enzyme, and component II comprises one or more compounds that are converted by said at least one enzyme released by said necroses into a cytotoxic drug.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to a combination of substances (component I) inducing necrosis in tumors or inflamed tissue with other nontoxic substances ("prodrugs", component II). The enzymes set free by necrotic processes then cleave the nontoxic "prodrug" into the toxic "drug", which leads to massive tumor cell death and/or remission of inflammation.
-
Citations
14 Claims
- 1. A pharmaceutical composition for use in cytostatic or immunotherapy, comprising a component I and a component II, wherein said component I comprises at least one compound that produces necroses a in tumor or in an inflammatory process, said necroses resulting in the release of at least one enzyme, and component II comprises one or more compounds that are converted by said at least one enzyme released by said necroses into a cytotoxic drug.
-
13. A pharmaceutical composition comprising a first component and a second component, said first component comprising a tissue necrosis factor and a second component comprising a prodrug activated by a product of the action of said first component, said first component consisting of a monoclonal antibody specific for the VEGF/VEGF receptor complex, and said second component consisting of N-(4-β
- -glucuronyl-3-nitrobenzylcarbonyl) doxorubicin.
- View Dependent Claims (14)
Specification